Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Richard Greil, Pavla Kadlecová et al.|Blood|2015Cited by 186
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2bNicole C.C. Them, Róbert Královics, Klaudia Bagienski et al.|American Journal of Hematology|2014Cited by 54
Intensive consolidation with G‐CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 yearsWolfgang R. Sperr, Peter Valent, Susanne Herndlhofer et al.|American Journal of Hematology|2017Cited by 11
Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera StudyHeinz Gisslinger, Richard Greil, Veronika Buxhofer‐Ausch et al.|Blood|2013Cited by 9
AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)Heinz Gisslinger, Josef Thaler, Róbert Královics et al.|Blood|2012Cited by 5